@article{oai:hsuh.repo.nii.ac.jp:00008692, author = {政所, 明弘 and 中出, 修 and 服部, 裕歩 and 賀来, 亨 and 五十嵐, 清治}, issue = {2}, journal = {東日本歯学雑誌}, month = {Dec}, note = {P(論文), We have recently demonstrated that melatonin stimulates proliferation and type I collagen synthesis of normal human osteoblastic cells in vitro. We have further shown that daily I.P. injection of melatonin could increase cancellous bone mass in young growing mice in vivo, indicating that melatonin may possess beneficial effects on bone. The present study was to determine the effects of oral administration of melatonin on bone in vivo. In addition, we examined the effects of melatonin (1 to 500μM) on osteoclastic activity using dentin-resorption-pit assay formed in vitro and the results were as follows. 1. Oral administration of melatonin (0.1 or 1 %) did not significantly affect the body weight of the mice. 2. Oral melatonin did not cause any pathological changes in several internal organs including hearts, lungs, liver, kidneys and spleen in mice. 3. Oral melatonin did not significantly affect either length or width of femur or tibia in mice. 4. Bone histomorphometric analyses of the proximal tibia indicated that oral melatonin significantly increased the cancellous bone volume. 5. Oral melatonin significantly decreased the bone formation parameters such as osteoblast surface and osteoid volume and at the same time it significantly decreased the resorption parameters such as resorption surface and osteoclast number. 6. Melatonin (25 to 500 μM), in vitro, caused dose-dependent reduction in number of resorption pits formed by osteoclasts derived from bone marrow cells but not those formed by purified rabbit osteoclasts. These results indicate for the first time that oral administration of melatonin could increase cancellous bone mass in young growing mice, most likely by suppressing bone resorption through indirect modulation of osteoblastic secretory factors.}, pages = {145--158}, title = {メラトニンの経口投与が骨代謝に及ぼす影響}, volume = {20}, year = {2001} }